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Résumé: 
Etat des connaissances: 
Les Accidents vasculaires cérébraux (A VC) sévères sont une cause importante de mortalité et 
de handicap en Suisse. Les buts de cette étude sont de déterminer les caractéristiques des 
patients avec un A VC à présentation initiale sévère "severely presenting", ainsi que 
d'identifier les facteurs prédicteurs en phase aigüe et subaigüe d'un devenir favorable chez 
ces patients. 
Methodologie: 
En utilisant le registre des A VC "Acute STroke Registry and Analysis of Lausanne 
(ASTRAL), nous avons comparé tous les patients avec un AVC "à présentation sévère", 
defini comme un score National Institute of Health Stroke Scale (NIHSS) 2: 20 à l'admission 
aux urgences, avec tous les autres patients du registre. Dans une analyse statistique 
multivariée, les associat10ns avec les caractéristiques démographiques, cliniques, 
pathophysiologiques, métaboliques et radiologiques des patients on été determinées. Dans un 
deuxième temps, nous avons analysé les facteurs prédicteurs d'un devenir favorable à 3 mois 
(modified Rankin scale (mRS) ::;3) dans ce groupe d' AVC à présentation sévère. 
Resultats: 
Parmi les 1'915 patients consécutifs, 243 (12.7%) présentaient un AVC rejoignant la 
définition de sévère. Ceux-cis étaient associés de manière significative avec un méchanisme 
ischémique cardio-embolique (OR=l.74 / 95% CI 1.19 - 2.54), un début inconnu de la 
symptomatologie (0R=2.35 / 95% CI 1.14 - 4.83), avaient plus de trouvailles d'origine 
ischémique aigüe lors de l'imagerie d'entrée (la majorité sont des CT-scan, 0R=2.65 / 95% 
CI 1.79 - 3.92), plus d'occlusions dans l'imagerie vasculaire d'admission (OR=27.01 / 95% 
CI 11.5 - 62.9), moins d'anciens infarctus cérébraux sur l'imagerie (OR=0.43 / 95% 0.26-
0.72), un taux d'haemoglobine plus bas en g/l (OR=0.97 / 95% CI 0.96 - 0.99), un taux de 
leucocytes plus élevé par 1000 cells/l (OR=l.05 / 95%CI 1.00 - 1.11). parmi les 68 (28%) 
patients avec un devenir favorable malgré un A VC initialement sévère, leur évolution 
favorable à été associée avec un âge plus jeune (OR=0.94 / 95% CI 0.92 - 0.97), la présence 
d'évenements cérébrovasculaires antécédants (OR=3.00 / 95% CI 1.01 - 8.97), un traitement 
hypolipémiant déjà présent (OR= 3.82 / 95% CI 1.34 - 10.90), une température corporelle 
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d'admission plus basse (OR=0.43 / 95% CI 0.23 - 0.78), une concentration subaigüe de 
glucose plus basse (OR=0.74 / 95% CI 0.56 - 0.97), et une recanalisation spontanée ou par 
thrombolyse à 24h (OR= 4.51/95%CI 1.96 - 10.41). 
Conclusion: 
les A VC à présentation initiale sévère sont associés à des facteurs prédicteurs cliniques, 
radiologiques, et métaboliques multiples, dont certains sont modifiables. Les facteurs 
prédicteurs des 28% de patients avec un devenir favorable en dépit d'un A VC intitialement 
sévère sont un pré-traitement par hypolipémiants, une temperature corporelle plus basse à 
l'admission, une glycémie plus basse à 24heures et la recanalisation artérielle. 
Travail de Thèse: 
1. Background and current knowledge 
1.1 Introduction 
Acute ischemic stroke (AIS) is the third leading cause of death after cardiac diseases and 
cancer. In the industrialized world, stroke is also the most frequent cause of acquired 
disability in adults 1 2. With a prevalence of 300/100,000 patients per year stroke represents a 
major societal burden in terms of both mortality and on-going patient care. Interestingly in 
Switzerland, the overall crude mortality rates in 2006 were 25/100,000 in women and 
31/100,000 in men which are among the lowest in the world3. 
1.2 Severely presenting strokes 
"Severely presenting stroke" is defined by a National Institute of Health Stroke Scale 
(NIHSS) score 220, and is also known as malignant cerebral infarction if the total territory of 
the middle cerebral artery is infarcted. Malignant middle cerebral artery (MCA) territory 
strokes have a poor prognosis. This is partially due to the risk developing a cerebral oedema 
and herniation that can lead to coma or brain death, which happens more often in young 
patients [30-31]. They often present with early reduced consciousness and progress to coma 
and brain death within 2 to 5 days in almost 80% of patients treated only with conservative 
medical therapy. Survivors of this form of stroke are severely disabled with poor quality of 
life [30]. Their incidence is estimated at 2-10% of all ischemic strokes4. Patients with 
malignant MCA infarction are also at increased risk of adverse outcome or death due to 
stroke-related complications such as pneumonia5, acute cardiac failure6. 
A better lmowledge of the risk factors and the relation between the patients' characteristics 
and their long term outcome would thus be useful towards patient management in the acute as 
well as subacute phase. Patients' information regarding their condition would be more 
accurate and research protocols concerning stroke would of course also benefit from these 
findings. 
1.3 Etiology, mechanisms 
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Commonest stroke mechanisms are embolism, mainly from a cardiac source, or from 
extracranial arteries. Compared to less severe strokes, massive brain ischemia seems to be 
more often caused by cardiac emboli and less by large artery occlusive mechanisms.7 
1.4 Imaging and localisation 
Apart from the underlying pathophysiologic mechanism, neuroimaging is another means 
which may hold promise in identifying stroke patients with potentially worse outcomes. Non-
contrast computed tomography (CT) is recommended in the acute phase of stroke to detect 
early ischemic changes suggestive of evolving ischemia and hypodensities which are highly 
predictive of completed infarction. 3-13 
1.5 Prognostic factors & Outcome 
Initial stroke severity, hyperglycemia, increasing age, infarct volume, underlying cardio-
embolic or dissection as pathophysiologic mechanism and fever 17' 18 are consistently 
associated with worse outcome. With less evidence, the following factors might predict worse 
functional recovery after stroke: poor pre-morbid status, cognitive impairment, reduced 
consciousness at onset, pre-existing hemiplegia, homonymous hemianopia, visual extinction, 
constructional apraxia, non-stroke unit care, visuospatial symptoms, urinary incontinence and 
female gender19.The most robust predictors of disability at 5 years after stroke are increasing 
age, recurrent stroke, and severity at onset20 The latter may be graded according to 
neurological scores such as NIHSS. 
NIHSS score within 24hours after symptoms' onset is related to the volume of infarcted 
cerebral tissue measured on CT at 7 days21 . The initial score allows a more reliable prediction 
of the residual disablement of a patient than other existing scales22 . Its utilisation in large 
clinical trials has now helped to define thresholds, that still need confirmation by further 
work: a score <10 before the third hour predicts a 40% chance to fully recover, whereas 
complete recovery is almost never the case when this score is >2023 . Moreover, previous work 
has shown that NIHSS score > 15 within 24h after stroke onset leads to an increase of 
hemorrhagic transformation by 15% if the patient receives anticoagulation at therapeutic 
levels24. 
Sorne patients with initially severe strokes may show excellent recovery. The following may 
be useful markers of patients more likely to improve: young age, small lesion size, early 
arterial recanalisation (spontaeous or interventional), absence of pre-stroke disability, 
normothermia and normoglycemia25 . 
Identifying these high risk patients at an early stage prior to the development of irreversible 
injury is essential so that evidence-based therapies such as intravenous or intra-arterial 
thrombolysis or even hemicraniectomy can be applied. Accurate prognostication may also 
identify patients in need of intensive monitoring and may guide rehabilitation strategies. 
2. Project Description: 
This project is divided in two parts: 
In the first one, we aim to study the epidemiology of severely presenting strokes: we want to 
characterise better what defines a severely presenting stroke, in terms of demographical, 
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clinical, biological and radiological caracteristics. What kind of acute and subacute 
caracteristics are especially seen in patients presenting such a subtype of stroke. 
In the second one, we aim to define the predictors (in the acute as well as subacute phase) of 
good recovery after stroke by means of the modified Rankin score (mRS) at 3 month after the 
event. 
The overall aims of this project are to identify: 
• Which stroke patients are at risk of developing a severely presenting stroke. 
• The predictors of good outcome in these patients. 
3. Methods 
3.1 Patients 
Inclusion criteria: 
All consecutive patients with acute ischemic stroke admitted to the stroke unit and/or 
intensive care unit of the CHUV, which is a community hospital for a population of circa 350 
000, as well as the only Stroke Unit for 720 000 persans, within 24hours from January 2003 
to December 2010. Data of these patients were prospectively included in the Acute STroke 
Registry and Analysis of Lausanne (ASTRAL)26. The ethics commission for research on 
humans of the Canton of Vaud, subcommission III, has approved the scientific use of 
ASTRAL. 
Exclusion criteria: 
In ASTRAL: Patients with ischemic stroke whose last proof of good health was > 24 hours 
before hospital arriva!, patients with haemorragic strokes (intracerebral hemorrhage, 
subarachnoid hemorrhage), and patients with transient ischemic attacks (TIA) as defined by 
complete remission of symptoms and signs within 24 hours were excluded. 
In this project: For part 1, we included all ASTRAL patients, and for part 2, we excluded 
patients with a NIHSS score <20. 
Fig 1: Identification 
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3.2 Stroke classification 
The classification used in this registry is the TOAST (Trial of Org-10172 in Acute ischemic 
Stroke) classification 27 with some modifications according to recent progress of research in 
this field28 : 
1. Large artery atherosclerosis (ipsilateral stenosis of >50% or occlusion) 
2. Likely atherothrombotic stroke 
• Ipsilateral internal carotid stenosis or another intra/extra cranial artery 
stenosis of < 50% or 
• Aortic arch plaques > 4 mm in thickness without a mobile component or 
• History of myocardial infarction or coronary recanalization or 
• At least two of the following: 
• Arterial hypertension or hypertensive retinopathy 
• Diabetes mellitus 
• Current smoking 
• Dyslipidemia 
3. Cardioembolic stroke 
4. Lacunar stroke 
5. Arterial dissection 
6. Acute stroke of other determined origin 
7. Undetermined etiology 
8. Coexisting and multiple causes 
9. Stroke attributed to patent foramen ovale 
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The NIHSS Scale 
This score has been described by T. Brott in 198929 to evaluate the severity of ischemic stroke 
in the acute phase. It is very practical and widely used in both research and clinical practice 
and has been validated for both carotid and vertebro-basilar strokes. The average time spent to 
complete this evaluation is 6'30", and the inter-observer reproducibility has been improved 
recently by an video e-learning program and international guidelines on the way one should 
perform the test11 . 
The limitations of this scale include its significant interobserver variability and the modest 
correlation relation between stroke severity and the size of the infarct with some large strokes 
leading to only moderate NIHSS (eg. a complete infarct of the posterior cerebral artery gives 
a score of 10). Moreover, a given score may represent different clinical deficits, which may be 
associated with different prognosis (both a moderate central paresis of nerve VII and a severe 
aphasia correspond to a score of 2) 
The sensitivity of this scale is limited by the number of items tested and by the low range of 
grades within the scale, but this limit aims to increase to inter-observer reproducibility, which 
is especially necessary for clinical trials. This lack of sensitivity has been criticised on the 
evaluation of clinical improvement or worsening of patients29 , except in minor strokes with no 
functional impairment, where functional scales are useless due to their threshold-effect. This 
is one of the reasons that we employ mRS in the second part of this project to assess patients' 
functional outcome in time. In this project, despite its known limitations in assessing different 
vascular territories, we used this scale with an arbitrary eut-off of 20 or above on admission to 
define severe strokes. 
The modified Rankin Scale (mRS) 
The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of 
disability or dependence in the everyday life of stroke patients, and it is widely used as a 
clinical outcome measure in stroke clinical trials. It was originally introduced in 1957 by 
Rankin. The first publication of the current modified Rankin Scale was in 1988 by van 
Swieten et al., who also published the first interobserver agreement analysis of the modified 
Rankin Scale30. Interobserver reliability of mRS can be improved by using a structured 
questionnaire during the interview process31 and by having raters undergo a multimedia 
training process32. In this project mRS was assessed by mRs-certified personnel at 3 months 
in the outpatient clinic. At 12 months, and for patients unable to attend the 3 month outpatient 
clinic, mRs was assessed by a structured telephone interview by mRs-certified personnel. 
Fig. 2 : Project overvieiv. 
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Base li ne 
Analysis 1 
Analysis 2 
3.4 Other information collected 
In addition to the above mentioned data, we collected detailed information in the following 
areas: 
• Demographics (Patients' age, gender, ethnicity and insurance, pre-existing vascular 
risk factors, the mode of transport to CHUV) 
• Cerebrovascular risk factors 
• Previous clinical TIA, stroke or ocular ischemia 
• Medication at the time of stroke onset 
• Timing of onset of symptoms or last well time (if onset is unknown), time of arrival, 
time intervals from stroke onset to brain imaging, to intervention (if not 
contraindicated). 
• Clinical symptoms and signs 
• NIHSS on admission, 24 hours, and 7 days, 
• modified Rankin scale before and 7 and 90 days after the stroke. 
• Clinical follow up at 3 month (NIHSS and mRS) and 12month (mRS). The 3 months 
outcome data were collected either during follow-up consultation in persan or by 
phone with the patients or relatives. 
• Acute and subacute neuroimaging (parenchymal imaging within 6 hours after 
admission) 
• Acute and subacute arterial imaging (mostly CT-angiography) 
• Laboratory examinations 
• Intervention details (thrombolysis, mechanical recanalisation, hemicraniectomy) 
2.5 Statistical analysis 
For the first part of this project, all ASTRAL patients are sepatated in two groups, where 
their NIHSS score at admission (NIHSSadm) is the dependent variable : 
• Group S (Severe) includes patients with a severely presenting stroke with a 
NIHSSadm ~20 
• Group 0 (Other) includes patients with a NIHSSadm < 20 
For the second part of this project, all patients from the « Severely presenting » Group (see 
part 1) will be sepatated in two groups, where their mRS score at 3 months (mRS 3m) is the 
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dependant variable : patients will be separated into a favourable (F) and a unfavourable (UF) 
outcome 
Outcome 
Unfavourable 
Modified 
Score 
0 
1 
2 
3 
4 
5 
6 
Rankin Definition 
No symptoms at all 
No significant disability despite 
symptoms; able to carry out all usual 
duties and activities 
Slight disability; unable to carry out all 
previous activities, but able to look 
after own affairs without assistance 
Moderate disability; requiring some 
help, but able to walk without 
assistance 
Moderately severe disability; unable to 
walk without assistance and unable to 
attend to own bodily needs without 
assistance 
Severe disability; bedridden, 
incontinent and requiring constant 
nursing care and attention 
Dead 
We considered moderate disability in the independent group since we only included severe 
(NIHSS>20) patients in part 2 of the study. mRS score ::S3 is a common eut-off value in severe 
stroke such as haemorrhagic or posterior fossa stroke studies, and given the initially severe 
clinical picture making it a priori less probable to achieve a mRS of 0, 1 or 2. 
Part One: Comparison of characteristics and predictors of group S vs. group 0 after 
exclusion of patients according to ASTRAL requirements. A univariate analysis of the 
individual variables was conducted to assess differences between the two groups. For 
univariate comparison, we used the x2 test for continuous data (unless distribution is not 
normal, where we used the Q-Q plot). For categorical data we used the Wilcoxon test. 
Part Two: Analysis of Outcome : Within group S, we subdivided patients according to their 
outcome (favourable vs. unfavourable) at 3 months. We then compared the patients who had a 
favourable outcome despite the fact that they came in with a severe, severely presenting 
stroke. A univariate analysis of the individual variables was conducted to assess differences 
between the two groups. The variables which were significant in the univariate analysis 
(p<0.1, in order to decrease the risk of a type II error), were entered into a multiple logistic 
regression model to identify predictors favourable outcome in patients with severely 
presenting stroke. All analyses were conducted with the STATA 9.2 program. 
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Table A: variables included 
•Age 
•Sex 
•lnsurance 
• Atherosclerosis 
•Lacunar 
in the 
•cardiac & Patent Foramen Ovale 
•Dissection 
•Unknown 
•Other/rare/multiple 
•Hypertension 
•Diabetis 
•Cholesterol 
•Smoking 
•Atrial Fibrilation 
•CAD 
•Prosthetic mechanical valve 
•low (<35%) ejection fraction 
•old symptomatic stroke 
univariate 
•Antiplattelets (Acetylsalycilate, Clopidogrel, Asasantin) 
•Anticoagulants (oral, hepar,Low-weight Heparin) 
•Antihypertensive 
•Hypolipemic 
•Antidiabetic (oral or insu lin) 
•Systolic blood pressure 
•Diastolic blood pressure 
•Heart rate 
•Body temperature 
•Glycemia 
•Creatinin 
•Cholesterol 
• Hemoglobinemia 
•Hematocrit 
•White Cel! Count 
• Platelets cou nt 
•acute lesions 
•chonic lesions 
•in ischemic territory (and ischemic terr. +other terr.) 
•in non-ischemic territory 
•pre-stroke mRS 
•Time of stroke onset 
analysis 
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Table B: analysis of subacute variables (not included in multivariate model of part one). 
4. Results 
• NIHSS at 4-6 hours 
•NIHSS at 24 hours 
•NIHSS at 7 days 
•NIHSS at 3 month 
•modified Rankin Scale (mRS) à 3 month 
•lntravenous thrombolysis 
•Endovascular treatment 
•Decompressive craniectomy 
•Delay until intervention 
Part one: Defining the severely presenting stroke patients' profile. 
1915 Severely presenting stroke patients's clinical and paraclinical characteristics are 
described in Table A. Median age was 68.8 years., the population consisted of 43.9% women. 
243 patients (12.7%) belonged to the group Sand 1672 (87.3%) in group O. 
Table C : Results concerning the analysis of table A variables. (Univariate analysis) 
Patients' caracteristics 
De111ograplzics 
Age, mean (±SD) 
Female Sex, n, (%) 
Insurance status n, (%) 
Metaùolics 
Ali patients 
(n=1915) 
68.80 (15.49) 
840 (43.96) 
1526 (80.36) 
Systolic Blood Pressure (rnrnHg), rnean (±SD) 158.87 (28.53) 
Diastolic blood pressure, (rnrnHg), mean 89,21 (17.82) 
(±SD) 
Heart Rate (min-1), mean (±SD) 
Ternperature (0 C), rnean (±SD) 
Glucose (nm1ol/I), mean (±SD) 
Creatinine (nunol/l), meru1 (±SD) 
Hemoglobin (g/1), rnean (±SD) 
Hematocrit (% ),mean (±SD) 
total cholesterol (rnmol/l), mean (±SD) 
White cell cou11t (xl 03/1), meru1 (±SD) 
79.97 (18.05) 
36.39 (0.66) 
7.17 (2.95) 
96.75 (51.69) 
138.77 (32.88) 
41.05 (4.98) 
5.59 (4.47) 
8.65 (4.42) 
Severely 
presenting 
Group patients 
(S)(n=243) 
69.63 (16.88) 
130 (53.5) 
199 (82.57) 
156.44 (31.41) 
86.76 (20.91) 
83.78 (22.34) 
36.26 (0.80) 
7.55 (2.39) 
93.26 (44.75) 
132.86 (19.66) 
39.97 (6.28) 
5.59 (4.44) 
9.83 (4.73) 
Others Group 
patients (0) 
(11=1672) 
68.68 (15.27) 
710 (42.57) 
1327 (80.04) 
159.22 (28.08) 
89.57 (17.30) 
79.41 (17.27) 
36.41 (0.64) 
7.11 (3.02) 
97.27 (52.64) 
139.65 (34.33) 
41.21 (4.74) 
5.59 (4.48) 
8.48 (4.35) 
Odd Ratio 
(95%CI) 
1.004 
0.644 
0.846 
0.996 
0.991 
1.012 
0.703 
1.038 
0.998 
0.981 
0.950 
1.000 
1.064 
p-value 
0.37 
<0.01 
0.35 
0.16 
0.02 
<0.01 
<0.01 
0.05 
0.27 
<0.01 
<0.01 
0.98 
<0.01 
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Platelets (xlO'/l), mean (±SD) 231.53 (73.09) 
Risk factors (pre-existi11g or 11ewly 
discovered) 
Hypertension, n, % 1280 (66.91) 
Diabetes mellitus, n, % 303 (15.91) 
Active smoking, n, % 444 (23.53) 
Atrialfibrillation, n, % 482 (25.21) 
Coronary heart disease, n, % 284 (l 4.85) 
Prostetic valve, n % 59 (3.09) 
Low ejection fraction (<35% ), n, % 85 (4.56) 
Previous cerebrovascular event (stroke, TIA 28 (1.47) 
or retinal), n, % 
Medicatio11 at ad111issio11 
Aspirine, n, % 609 (32.12) 
Antiplatelets(Clopidogrel&ASA&Asasantine), 681 (35.92) 
n, % 
Anticoagulant, n, % 192 (10.16) 
Antihypertensive, n, % 1045 (55.23) 
Hypolipenùc, n, % 438 (23.16) 
Antidiabetics, n, % 155 (8.16) 
Strolœ 111ec111111is111 
Atherosclerosis (~50% stenosis), n, % 
Unknown or Atherosclerosis (<50%), n, % 
Cardiac or PFO, n, % 
· Lacunar/ microangiopathy, n, % 
Dissection, n, % 
Other/rare, n, % 
Multiple/coexisting, % 
Radiological Fiudi11gs (CT-Scm1 or MRI) 
254 (13.60) 
458 (24.53) 
617 (33.05) 
277 (14.84) 
92 (4.93) 
77 (4.12) 
92 (4.93) 
Arterial findings in ischemic territory 796 (49.91) 
(stenosis>50% or occlusion), n, % 
Acute Parenchymal findings, n, % 632 (35.53) 
Chronic parenchymal findings, n, % 
Old Strokes (radiologically), n, % 
Leukoaraiosis, 111 % 
Event circ11111sta11ces 
knov-.1n, n, % 
approximative(+ /-1h), n, % 
Unknown (>lh, but Jess than 24h, excluding 
\vake-up sh·okes), n, % 
During night sleep, n, % 
During day sleep, n, % 
pre-stroke 111odified Rm1ki11 Scale, 111e1111, 
(±SD) 
788 (47.21) 
514 (30.80) 
421 (25.22) 
1074 (56.11) 
260 (13.58) 
97 (5.07) 
445 (23.25) 
38 (1.99) 
0.69 (1.00) 
232.70 (85.59) 
140 (57.85) 
33 (13.75) 
46 (19.83) 
94 (38.84) 
37 (15.23) 
9 (3.73) 
20 (8.62) 
3 (1.23) 
72 (30.13) 
81 (33.89) 
29 (12.13) 
123 (51.9) 
41 (17.23) 
14 (5.83) 
30 (12.55) 
50 (20.92) 
118 (49.37) 
0 (0) 
18 (7.53) 
11 (4.60) 
12 (5.02) 
616 (88.24) 
149 (63.4) 
90 (40.18) 
55 (24.55) 
47 (20.98) 
126 (51.85) 
34 (13.99) 
32 (13.17) 
49 (20.16) 
2 (0.82) 
0.85 (1.17) 
231.35 (71.07) 
1140 (68.22) 
270 (16.22) 
398 (24.05) 
388 (23.23) 
247 (14.79) 
50 (2.99) 
65 (3.99) 
25 (1.5) 
537 (32.41) 
600 (36.21) 
163 (9.87) 
922 (55.71) 
397 (24.02) 
141 (8.52) 
224 (13.76) 
408 (25.06) 
4<)9 (30.65) 
277 (17.01) 
74 (4.75) 
66 (4.05) 
80 (4.91) 
180 (44.28) 
483 (31.28) 
698 (48.3) 
459 (31.76) 
374 (25.88) 
948 (56.73) 
226 (13.52) 
65 (3.89) 
396 (23.70) 
36 (2.15) 
0.67 (0.97) 
1.000 
0.639 
0.824 
0.781 
2.098 
1.035 
1.257 
2.271 
0.771 
0.899 
0.903 
1.261 
0.858 
0.658 
0.665 
0.900 
0.915 
1.766 
1.816 
1.244 
1.023 
9.436 
3.806 
0.719 
0.699 
0.760 
0.821 
1.040 
3.747 
0.813 
0.377 
1.178 
0.79 
<0.01 
0.33 
0.16 
<0.01 
0.86 
0.53 
0.02 
0.11 
0.48 
0.48 
0.28 
0.27 
0.02 
0.16 
0.61 
0.72 
0.01 
(not 
analysable) 
0.07 
0.56 
0.76 
<0.01 
<0.01 
0.02 
0.03 
0.12 
0.15 
0.84 
<0.01 
0.22 
0.18 
0.01 
The univariate comparison between the two groups showed significant differences between 
the two groups for certain variables listed by category below 
Epidemiology: Patients m the severely presenting group are more likely to be females 
(53.50%). 
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Acute metabolic and physiologie values : Severely presenting stroke patients have a 
higher heart rate and WCC at admission, but acute diastolic blood pressure, body temperature, 
hemoglobin and hematocrit were significantly lower in the severely presenting stroke group. 
Risk factors and medication : Hypertension was less frequent in group S, but atrial 
fibrillation and heart failure (low ejection fraction) was more common. At admission severely 
presenting stroke patients are less frequently under hypolipernic treatment. 
Stroke mechanism : a higher percentage of dissection and cardiac etiology are leading to a 
severely presenting stroke. 15% of the patients in the « others » group had a lacunar etiology 
to their stroke, yet not a single stroke in the severely presenting group had this etiology. 
Radiology: Occlusion or stenosis of the cervical/cerebral vessels are more frequent in the 
severely presenting group. Moreover, imaging studies analysis showed that these patients 
have less old ischemic lesions and leukoaraiosis than non-severely presenting stroke patients. 
Stroke circumstances : For most of the patients, the exact time of stroke onset is known, 
but the proportion of unknown symptoms onset is significantly more frequent in severely 
presenting stroke patients (13% in the severely presenting group vs 5% in the others group). 
Pre-stroke conditions : pre-stroke Independence measured by mRS was higher in the 
severely presenting stroke patient population than in the others stroke patient population. 
The results of the univariate analysis of variables in Table B not included in the multivariate 
analysis are listed in the Table D : 
Table D : of the univariate analysis of variables in Table B (not included in the multivariate 
analysis) 
Patients' caracteristics Ali Patients Croup S (n=243) Croup 0 (n=1672) Odd Ratio p-value 
(n=1915) (95%CI) 
Stroke severity 
Pre-stroke NJHSS, rnean, (±SD) 0.51 (1.46) 0.83 (1.99) 0.47 (1.38) 1.132 0.03 
NIHSS at 4h-6h, rnean (±SD) 8.19 (7.58) 22.81 (5.91) 6.08 (5.04) 1.556 <0.01 
NJHSS at 24h, mean (±SD) 7.65 (8.07) 22.07 (8.06) 5.55 (5.52) 1.318 <0.01 
NIHSS at 7 days, mean (±SD) 6.92 (9.99) 23.13 (12.81) 4.59 (6.88) 1.16 <0.01 
I11terve11tio11s 
J.V. Thrombolysis, n, % 302 (15.79) 72 (29.63) 230 (13.78) 2.726 <0.01 
EndovasculaT thrombolysis, n % 16 (0.84) 7 (2.88) 9 (0.54) 6.772 <0.01 
Delay between adnùssion and 80.83 (115.37) 91.61 (152.10) 77.41 (101.06) 1.001 0.32 
intervention, mean, (±SD) 
Crcmiectorny , n, ~·6 0.78 3.70 0.36 10.667 <0.01 
Patie11ts' 011tco111e 
modfied Rankin Scale at 3 rnonths, 2.33 (1.96) 4.55 (1.75) 1.99 (1.76) 1.881 <0.01 
111ean, 
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Interventions and acute patient management: In univariate comparison, severely 
presenting stroke patients undergo more frequentely an invasive treatment such as intravenous 
or endovascular thrombolysis, or hemicraniectomy than the others. On the contrary, time from 
arriva! at hospital to treatment (so-called « door-to-needle time ») of a group S patient is 15' 
longer compared to patients with a group 0 patient. 
Stroke severity and outcome: Both severely presenting (S) and other strokes (0) patients 
had a NIHSS which decreased gradually within the first 24hours, nevertheless, their evolution 
in the sub-acute phase was very different: between 24h and 7days, Group S patients showed a 
slight but steady increase of their NIHSS. On the contrary, group 0 patients evolved with a 
further reduction of the NIHSS score. As expected, the mRS score at 3 month was 
significantly higher in patients within group S (median : 4-5) than patients in group 0 
(median : 2). 
Results of Multivariate analysis ( extracted from significant values in Table C) are presented in 
Table E: 
Table E: multivariate analysis of predictors of severely presenting strokes. 
Patients' caracteristics 
Metabolics 
Hemoglobin 
: White cell count 
Strolœ Meclia11is111s 
Cardio-embolic 
Radiological Fi11di11gs (CT-Sca11 or MRI) 
Odd Ratio (95% CI) 
0.976, (0.965 - 0.987) 
1.054, (1.001 -1.109) 
1.744, (1.193 - 2.548) 
. Arterial findings in ischemic territory (stenosis>50% or occlusion) 0.037, (0.0158 - 0.0862) 
Any Acute Parenchymal Finding , (Leukoaraiosis, non vascular 2.655, (1.795 - 3.924) 
lesion, old stroke, other lesion) 
. Old Stt·okes (radiologically) 0.431, (0.258 - 0.719) 
Event circ11111stm1ces 
--Unknovm (>lh, but less than 24h, excluding wake-up sb·okes) 2.351, (1.143 - 4.831) 
pre-strolœ 111odified Ra11ki11 Sea le) 1.279, (1.041 -1.569) 
p-value 
<0.01 
0.04 
<0.01 
<0.01 
<0.01 
<0.01 
0.02 
0.02 
Among the 1917 patients with acute ischemic stroke included in this study, the multivariate 
analysis allows us to adjust for confounding factors when describing the severely presenting 
stroke population. According to our analysis, these patients have a higher pre-stroke mRS, 
lower haemoglobin, and a higher white cell count. Radiologically, they show less frequently 
old stroke lesions, more acute parenchymal findings and more arterial anomalies within the 
ischemic territory. Concerning the etiology, the cardioembolic and the arterial dissection were 
more frequent mechanisms in Group S compared to group O. Finally, we also observed that 
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the exact onset time of the stroke was less frequently known in the severely presenting stroke 
group. 
In order to assess the performance of our multivariate analysis, figure 3 presents the ROC 
curve, which shows that our model has an area under the curve of around 86%, which reflects 
that it is a good predictor of the patients' situation. 
0 
0 
0 
l!) 
0 
l!) 
"! 
0 
0 
0 
0 
0.00 0.25 
Area under ROC curve = 0.8608 
Fig. 3 : ROC curve. 
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Part two: Predicto.rs of good outcome in severely p.resenting stroke patients. 
In this part, we studied first (Tables F and G) the acute phase predictors of favorable outcome 
at three months within group S, including acute recanalisation treatments. This is to show 
which characteristics of stroke patients at the emergency ward will lead them to good 
outcome. We then added predictors collected in the subacute phase (24-48 hours after stroke), 
including subacute NIHSS values, metabolic values, recanalisation on repeat arterial imaging, 
and parenchymal findings in subacute neuroimaging. This is to see if we can better predict a 
patient's outcome once he is a the neurology ward. 
Table F : Univariate analysis of acute phase predictors of favourable outcome in group S 
patients. 
Patient's caracteristics Ail patients Favourable Unfavourable Odds Ratio p-value 
outco1ne outcorne (mRS 
(mRS 0-3 at 3 4-6 at 3 months) 
months) 
(N)% 243 (68) 28% (175)72% 
Age mean,(±SD) 69.63 (16.88) 61.45 (16.19) 72.80 (16.10} 0.960 <0.01 
Female Sex, n, % 30 (44.12) 160 (57.14) 1.680 0.07 
Private Insurance, n, % 17 (25.00) 25 (14.45) 1.973 0.06 
Metabolic~ &Physiologie 
Systolic blood pressure (nunl-Ig) mean,(±SD) 156.44 149.41(28.71) 159.19 (32.06) 0.989 0.03 
(31.41) 
Diastolic blood pressure (nmilig) mean,(±SD) 86.76 (20.91) 83.46(16.95) 88.05 (22.17) 0.989 0.13 
Heart rate (min-1) mean,(±SD) 83.78 (22.34) 80.87 (18.98) 84.92 (23.48) 0.99l 0.21 
Temperature (0 C) mean,(±SD) 36.26 (0.80) 36.07 (0.63) 36.33(0.84) 0.632 0.02 
Glucose (nm1ol/l) mea:n,(±SD) 7.55 (2.39) 6.85(1.88) 7.82(2.51) 0.811 0.01 
Serum creatinü1e (mmol/l) mean,(±SD) 93.26 (44.75) 84.21 (23.59) 96.72(50.17) 0.988 0.03 
Hemoglobine (g/l) mean,(±SD) 132.86 133.70 (21.29) 132.54(19.06) 1.003 0.68 
(19.66) 
39.98 (6.52) Hematocrit mean,(±SD) 39.97 (6.28) 39.92(5.66) 0.998 0.95 
Total cholesterol (mmol/l) mean,(±SD) 5.59 (4.44) 5.08(1.55) 5.77 (5.09) 0.943 0.37 
White blood cell count (x103/l) mean,(±SD) 9.83 (4.73) 9.93 (4.77) 9.79 (4.72) 1.006 0.84 
Platelet count (x103/l) mean,(±SD) 232.70 233.85 (73.58) 232.26 (89.97) 1.000 0.90 
(85.59) 
Risle factors (11ew or 11ewly discovemf) 
, Hypertension,n, % 140, (57.85) 32 (47.06) 174 (62.07) 0,543 0.04 
Diabetes mellitus,n, % 33, (13.75) 10 (14.71) 23 (13.37) 1.116 0.79 
Smoking,n, % 46, (19.83) 17 (25.76) 29 (17.47) 1.638 0.16 
A trial fibrillation,n, % 94, (38.84) 18 (26.47) 76 (43.68) 0.464 0.02 
CAD,n, % 37, (15.23) 13 819.12) 24 (13.71) 1.487 0.30 
Mechanic Valves,n, % 9, (3.73) 2 (2.99) 7 (84.02) 0.734 0.70 
Low Ejection Fraction (<35%),n, % 20, (8.62) 5 (7.69) 15 (88.98) 0.844 0.75 
Patie11t's History 
Previous cerebrovascular event (AVC, AIT or retinal 187, (78.24) 58 (87.88) 129 (74.57) 2.53 0.03 
ischenûa) ,n, % 
Medicatio11 at ad111issio11 
Anticoagulant,n, % 29, (12.13) 10 (14.93) 19 (11.05) 1.412 0.41 
Bath ASA & Anticoag,n, %. 81, (33.89) 15 (22.39) 66 (38.37) 0.463 0.02 
Antihypertensive treatement, n, % 123, (51.90) 33 (50.00) 90 (52.63) 0.900 0.72 
Hypolipemic, n, % 41, (17.23) 15 (22.73) 26 (15.12) 1.651 0.17 
Antidiabetics, n, % 14, (5.83) 5 (7.46) 9 (5.20) 1.469 0.51 
TOASTMeclza11is111 
Atherosclerosis (>=50% stenosis), n % 30, (12.55) 6 (8.96) 24 (13.95) 0.607 0.30 
Unknown Or atherosclerosis <50%, n, % 50, (20.92) 14 (20.90) 36 (20.93) 0.998 1.00 
Cardiac Or PFO, n, % 118, (49.37) 30 (44.78) 88 (51.16) 0.774 0.38 
Lacunar/ microangiopathy, n, % 0 0 
Dissection, n, % 18, (7.53) 9 (13.43) 9 (5.23) 2.810 0.04 
Other/rare, n, % 11, (4.60) 7 (10.45) 11 (2.33) 4.900 0.01 
Multiple/coexisting, n, % 12, (5.02) 1 (1.49) 11 (6.40) 0.222 0.15 
Arterial a11omalies (011 CT, if110 CT pe1for111ed, clieclœd 
011 MRI or Doppler: 
Arterial findings in ischemic territory , n, % 180, (88.24) 56 (90.32) 124 (87.32) 1.35 0.54 
(011 CT; if 110 CT pe1for111ed, 
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; Any Acute Parenchymal Finding , (Leukoarniosis, non 90, (40.18) 17 (28.33) 73 (44.51) 0.684 0.20 
vascular lesion, old sh·oke, other lesion), n, % 
Chronic parenchymal findings (leukoaraiosis & other), 86, (38.39) 17 (28.33) 73 (44.51) 0.544 0.06 
,n, % 
Old Strokes, n, % 55, (24.55) 13 (21.67) 42 825.61) 0.803 0.54 
Leukoaraiosis, n, % 47, (20.98) 7 (11.67) 40 (24.39) 0.409 0.04 
Acute imagi11g descriptio11 
**Any acute finding (Acute stroke, Asymptomatic 149, (63.40) 37 (56.92) 112 (65.88) 0.684 0.20 
n1ass, Hen1orragic transfonnation) n, % 
Ti111i11g of 011set 
Knovvn,n, % 126, (51.85) 44 (64.71) 82 (46.86) 2.079 0.01 
Approx,n, % 34, (13.99) 4 (5.88) 30 (17.14) 0.302 0.03 
During night sleep,n, % 49, (20.16) 12 (17.65) 37 (21.14) 0.799 0.54 
Unknovm (> 1h but Jess than 24h) ,n, % 32, (13.17) 7 (10.29) 25 (14.29) 0.688 0.41 
During day sleep,n, % 2, (0.82) 1 (1.47) 1 (0.57) 2.596 0.50 
Pre-cli11icnl stntus 
**Pre-sh·oke NIHSS mean,(±SD) 0.83, (1.99) 0.88(2.64) 0.81(1.70) 1.017 0.89 
mRSPreHosp mean,(±SD) 0.85,(1.17) 0.41(0.81) 1.02(1.24) 0.558 <0.01 
Illterve11tio11s 
IV-standard,n, % 72, (29.63) 32 (47.06) 40 (22.86) 3.300 <0.01 
IA-standard,n, % 7, (2.88) 3 (5.88) 3 (1.71) 5.500 0.03 
IVorIA,n, % 79, (32.51) 36 (52.94) 43 (24.57) 3.453 <0.01 
Craniecton1y,n, % 9, (3.70) 3 (4.41) 6 (3.43) 1.300 0.72 
**Timing of Intervention mean (per min.),(±SD) ,n, % 152.1, (91.61) 13.41(4.93) 13.00 (5.48) 1.000 0.39 
**: not included in multivariate model. 
Epidemiology: Age difference between the two groups is significant (61.45% vs 72.80%), 
which means that the older patients within group S have less chance to be independent at 
three months. Insurance status hasn't shown to be significant (OR: 1.97/p-val: 0.06) but 
there is a trend that seems to favor private patients. 
Acute metabolic and physiologie values : The only metabolic value at the emergency room 
that seems to influence outcome in stroke patients is glucose, as admission hyperglycemia 
was significantly associated with unfavourable outcome in the severely presenting stroke 
population. 
Timing of Onset: Known onset was significantly associated with favourable outcome in 
patients with severely presenting stroke. 
Pre-clinical status: pre-stroke functional status measured by mRS was significantly higher in 
unfavourable outcome severely presenting stroke patients. 
Interventions: Invasive treatement is efficient when applied according to ESO guidelines, 
as significantly more severely presenting stroke patients have a good outcome when they 
underwent LV. thrombolysis or LV. & I.A. thrombolysis together. I.A. intervention doesn't 
seem to influence the outcome so strongly (OR :5.5/ p-value : 0.03), but numbers are low. 
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In multivariate analysis of the acute phase (table G), favourable outcome was predicted by 
lower age and lower initial temperature. Private insurance status, lower pre-existing functional 
handicap, lower glycaemia and undertaking of recanalisation treatment also increased the 
probability of favourable outcome. If subacute variables were added in the multivariate 
analysis (table I), treatment with hypolipemic agents (mostly statins) increased the probability 
of favourable outcome. The pre-existing functional handicap was replaced by past 
cerebrovascular events, acute by subacute (24-48 hour) glycaemia, and recanalisation 
treatment by (therapeutic or spontaneous) recanalisation. The ROC-AUC for predicting 
favourable outcome after severe stroke using the acute variables was 82%, and 81 % when 
adding the subacute variables. 
Table G: Multivariate analysis of acute phase predictors of favourable outcome in patients 
with initially severely presenting stroke. 
Patient's caracteristics Odd Ratio (95% CI) p-value 
Pre-strolœ status 
Pre-stroke mRS 0.622, (0.405 - 0.954) 0.03 
Dcmagmpltics 
Age 0.952, (0.929 - 0.975) <0.01 
Private InsUl'm1Ce 2.517, (1.058 - 5.988) '?? 
Metabolics 
Acute Temperature(') 0.423, (0.239 - 0.745) <0.01 
Acute Glucose 0.746, (0.612 - 0.908) <0.01 
Interve11tio11 
Intervention (I.V. or'i.A.) 2.476, (1.207 - 5.081) 0.01 
ROC Curve: 
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Table H: Univariate analysis of subacute predictors of favourable outcome in patients with 
initially severely presenting stroke 
Patient's caracteristics Ali patients Favourable Unfavourable Odds Ratio p-value 
outcorne (rnRS 0- 4-6 at 
3 at 3 rnonths 
N ("/ci) 243 (100%) 69 (28%) 174 (72%) 
Subnrnte 111etnbolic vn/11es 
Systolic blood pressure (mmHg) mean,(±SD) 143.47 (21.93) 139.78 (21.90) 145.07 (21.81) 0.989 0.1 
Diastolic blood pressure (mmHg) mean,(±SD) 68.70 (15.63) 67.55 (15.78) 69.19 (15.59) 0.993 0.472 
Heart rate (nûn-1) mean,(±SD) 82.55 (18.32) 76.25 (16.68) 85.26 (18.38) 0.970 <0.01 
Temperature (0 C) mean,(±SD) 37.01 (0.70) 36.89 (0.74) 37.06 (0.68) 0.694 <0.01 
Glucose (nuuolfl) mean,(±SD) 6.41 (1.93) 5.93 (1.24) 6.65 (2.16) 0.772 0.02 
Serum creatinine (mmolfl) mean,(±SD) 89.53 (71.77) 79.19 (25.44) 93.48 (82.67) 0.990 0.16 
Hemoglobine (gll) mean,(±SD) 126.59 (19.56) 124.48 (20.79) 127.53 (19.03) 0.992 0.4 
Hematocrit mean,(±SD) 38.04 (5.38) 37.19 (5.32) 38.41 (5.39) 0.958 0.22 
Total cholesternl (mmolfl) mean,(±SD) 8.12 (9.37) 4.84 (1.06) 9.76 (11.22) 0.904 0.35 
Wlûte blood cell count (xl03/l) mean,(±SD) 11.21 (3.91) 10.69 (3.33) 11.45 (4.13) 0.948 0.29 
Platelet count (x103/l) mean,(±SD) 215.95 (74.33) 218.71 (67.46) 214.71 (77.52) 1.00 0.77 
S11bnc11te i111ngi11gfi11di11gs 
Any finding (acute stroke, HT, mass effect, other) , 150, (96.15) 51 (92.73) 99 (98.02) 0.257 0.13 
n, 0/o 
S11bnc11te vnsrn/nr i111ngi11g 
Significant Pathology in non-isch terrilory or none, 38, (32.76) 18 (40.00) 20 (28.17) 1.7 0.19 
n, (1'1 
Atherontatose :yes, n, 0/c:i 33,(57.89) 9(42.86) 24(66.67) 0.375 0.08 
Reca11alisatio11 
Ü\•erall Complete, n, '% 26, (11.16) 18 (26.47) 8 (4.85) 7 <0.01 
Overall in1prove1nent, 11, 0;;1 40, (17.1_7) 17 (25.00) 23 (13.94) 2.05 0.04 
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Overall not, n, c'll1 67, (28.76) 15 (22.06) 52 (31.52) 0.615 0.15 
Overall don'f know/nof checked, 11, •y., 71, (30.47) 10 (14.71) 61 (36.97) 0.293 <0.01 
Overall occlusion or stenosis in ischemic ferr. 29,(12.45) 8 (11.76) 21 (12.73) 0.914 0.84 
never seenfdocumented, n, 'Yu 
Overall: yes (complete, partial, improvemenl) , 11, 66, (28.33) 35 (51.47) 31 (18.79) 4.58 <0.01 
%1 
excracranial Recanalisation :yés ( complete, 20, (8.55) 6 (8.82) 14 (8.43) 1.05 0.92 
ÎI11prove1nent) , n, 'Yo 
intracranial Recanalisation: yes(complete, 63, (27.16) 37 (54.41) 26 (15.85) 6.33 <0.01 
intprove~t~nt / n, %1 
Worstening of arterial patency (no, don't know, 225, (96.57) 65 (95.59) 160 (96.97) 1.47 0.6 
not documented) , n, 'Y.• 
S11bac11te NIHSS values 
**NIHSS at 24h (or change score. or CoVarlance 22.07, (8.06) 15.13 (7.79) 24.67 (6.47) 0.807 <0.01 
between NIHSS adm and NIHSS 24h), mean,(±SD) 
**NIHSS at 7 days (or change score or covariance 23.13, (12.81) 12.01 (8.31) 27.56 (11.55) 0.852 <0.01 
betwee11 NIHSS adm at NIHSS 7d), mea11,(±SD) 
Orie11tatio11 
Death, 11, 0;(, 84, (36.52) 0(0) 84(50.91) Not 
calculable 
Home or short stay, 11, % 11, (4.78) 9(13.85) 2(1.21) 13 <0.01 
Long tenu instutution, n, % 14, (6.09) 0(0) 14(8.48) Not 
calculable 
Other acute care hosp, 11, % 41, (17.83) 19(29.23) 22(13.33) 2.68 <0.01 
rehabilitation, n, % 80, (34.78) 37(56.92) 43(26.06) 3.74 <0.01 
Table 1: Multivariate analysis of acute and subacute predictors of favourable outcome in 
patients with initially severe stroke. 
Patient' s caracteristics 
Patie11t's llistory 
Previous cerebrovascular event (Stroke, TIA, retinalischem:ia) 
Patieut 111a11age111e11t 
Hypolipemic treatement 
Metabolics 
Acute Temperature(0 ) 
Subacute Glucose 
De111ogmpllics 
Age 
Arterial i111agi11g 
Overall recanalisation 
ROC curve: 
Odd Ratio (95°/., CI) 
3.00, (1.009 - 8.964) 
3.82, (1.3'11 - 10.895) 
0.427, (0.232- 0.785) 
0.739, (0.565 - 0.966) 
0.943, (0.917 - 0.971) 
4.51, (1. 957 - 10.407) 
p-value 
0.04 
0.01 
<0.01 
0.02 
<0.01 
<0.01 
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Since severely presenting stroke is a dangerous and disabling condition, it is of prime 
importance to have a sensitive screening profile of the patients with suspicion of severely 
presenting stroke. 
Analysis 1: Profile of Seve rel y presenting stroke patients. 
In the first part of this project, we were interested in defining the profile of patients that suffer 
a severely presenting stroke. 
Previous studies33• 34 have shown that young patients are more at risk to develop a severely 
presenting stroke with a mass effect. However, the results from our work didn't show any 
association between age and the characteristics of severely presenting strokes, despite the fact 
that age distribution was similar across all stroke types. 
There was significantly more women in the severely presenting stroke group in the univariate 
analysis, which confirms a recent report 19 . In our population, gender did disappear during in 
the multivariate analysis, showing that this previous idea was not significant. Sex is hence a 
bad predictor of stroke severity. Similarly, pre-existing hypertension and pretreatment with 
hypolipemic agents were negatively associated with severe stroke in the univariate, but not in 
the multivariate analysis. 
Our study helps evaluate which stroke etiology is the most frequent in patients with a severely 
presenting stroke. We showed that patients with an arterio-embolic stroke mechanism are at 
less risk to develop a severely presenting stroke. This can partially be explained by the fact 
that atherosclerosis is a chronic disease that evolves over decades, thus allowing collateral 
vascularisation to develop and potentially compensate for the vessel occlusion up to a certain 
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degree33 ' 35 These results are congruent with data recently shown by our group regarding 
patient's outcome after proximal MCA occlusion36 
Moreover, we see in this study that no severely presenting stroke was caused by 
microangiopathy. Understandably, by definition25 ' 37 lacunar strokes don't cause the ischemia 
of a whole vascular territory. 
Third, the cardio-embolic origin of stroke was significantly more frequent in patients with a 
severely presenting stroke, as also shown by previous studies38• 39 
Finally, dissection is a known cause of severely presenting strokes (7.5% of dissections lead 
to group S, and 4.7% lead to group 0). The large blood supply by the extracranial vessels 
explain the important ischemia induced by their occlusion40. 
Radiological data (mostly CT and CTAngio) revealed that both parenchymal and arterial 
findings in the ischemic territory are significantly more frequent in patients with a severely 
presenting stroke. This seems counterintuitive given that functional compensation for cerebral 
damage depends partially on the remaining "healthy" brain. However, patients who have less 
severe strokes might have a higher likelihood of having survived other nùnor strokes in the 
past. In addition, such survivors of previous strokes may receive better secondary prevention 
treatments, which have been shown to not only decrease recurrence, but also the severity of 
recurrent strokes. 
The high prestroke mRS is leading to more risk belonging to group S. This shows that 
patients already disabled after a first event have less ability to compensate for new deficits. 
Eventually, the exact time onset of the stroke is more often unknown in group S. The inability 
of the patient to express himself or to remember the early symptoms is probably the reason of 
this finding. The reason that this is not the case for sleep-onset stroke may be that such strokes 
are more frequently lacunar. 
Severely presenting strokes more often received an intervention, such as thrombolysis or 
hemicraniectomy. This result seems reasonable, because the group was defined on clinical 
status of the patient, and the indication of thrombolysis as well. We also know that mass 
effect risk is higher in the severely presenting stroke type of patients 42' 43 which explains 
more surgical intervention. 
Severe strokes were more frequent in patients with lower haemoglobin levels, suggesting that 
decreased oxygen transport capacity may increase infarct size. 
White cell count has previously been associated with more severe clinical presentation and 
with worse early stroke outcome. It is not clear whether this is a direct effect of white cell 
activity and inflammation in the lesioned brain, or whether it is rather a marker of 
associated conditions (e.g. fever, early infection, stress response) that may increase 
stroke severity and worsen outcome. 
The NIHSS score, assessed at different times during hospitalisation, didn t evolve similarly 
between the two groups: In group A, NIHSS follows a decreasing pattern , which is not the 
case for group S, where the NIHSS increases again between 24hours and 7 days. This result is 
probably due to the clinical complications shown by severely presenting stroke patients, such 
as brain edema and hem01rngic transformation4• 33 • 42• 43 . 
Regarding HT according to ECASS-2 definition, unfavourable outcome was associated with 
greater HT. However, the rate of hemorragic transformation cannot really be judged since it 
concerned only 3 out of the 243 patients in the acute phase. 
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In this study, the NIHSS at admission value was used as a dependent variable, it is why it is 
very interesting and important to study how this time point will have an influence on the 
evolution of the patient's affection. In analysing the mRS at 3month, we saw that 28% of the 
patients have a good outcome (mRS between 0 and 3 at 3 months). Previous studies had 
already shown certain predictors of good outcome in stroke patients, but not precisely in 
severely presenting stroke patients. This is why we performed analysis two, whose results are 
now discussed. 
Analysis 2 : Good outcome in severely presenting stroke patients : acute and 
subacute predictors. 
Severely presenting stroke patients are a specific type of patients, as we saw in the first part of 
this project. Few of them show a positive evolution of their neurologie situation (28%) and 
these patients are of main interest because they can lead us towards a better management of 
severe stroke patients in the acute phase as well as in the subacute phase, by identifying 
whether there are factors that can be modified in their profile, or if their evolution is mainly 
defined by their constitutional or demographic characteristics. 
In the acute phase alone, the fact that increased age predicts significantly unfavorable 
outcome in group S patients. This situation can be attributed to two factors : on one side, the 
vulnerability of old patients when it cornes to lesion size tolerance : reduction of the number 
of synapses in old age 44, diminished volume of cortical grey matter 45 and thus neuronal 
plasticity, which is diminished in old patients, and on the other side their ability to improve as 
much as young patients 46 in the rehabilitation period, which is also reduced. 
Private insurance status - probably indicating a higher socioeconomic status - has previously 
been show to predict favourable outcome in stroke patients47 . The reasons for this observation 
are not certain, although one of our previous studies showed lower initial stroke severity in 
privately insured patients; this was not confirmed in the current dichotomised study. 
One last characteristic is a significant predictor in the multivariate analysis: temperature. 
Increased temperature at admission is associated with less favorable outcome at 3months, 
implying that tight monitoring of temperature from admission to the ward is important. 
Understandably less inflammatory conditions benefit towards a better patient prognosis. 
Febrile patients also might have other comorbidities influencing the outcome. This effect can 
also be understood by the fact that severely presenting stroke patients very often suffer 
dysphagia in the acute phase, leading to broncho-aspiration and further fever and pneumonia, 
the main complication after stroke48 which has been shown to influence outcome of stroke 
patients49 . The fact that hyperglycemia was correlated with unfavorable outcome at 3 months 
was also to be expected. We already knew that the glycemia in the acute phase influenced 
stroke patients prognosis 50 so this finding confirms the same situation for severe stroke 
patients. 
Interestingly, stroke etiology doesn't show to be signi:ficant in the model; this could be due to 
the fact that as we already saw in part one, there were no lacunar strokes in the severely 
presenting stroke group, so this was a more or less a homogenous group regarding outcome. It 
also shows that in severe strokes, the probablility to find an occlusion is very high, which 
probably explains that the outcome is more dependent on the patients's vascular status than 
the stroke's etiology. This is also probably the reason why this type of patients benefit from 
thrombolysis. 
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Another reason why severely presenting stroke patients have a better outcome when 
thrombolysed rnight be patient selection : regarding state-of-the-art thrombolysis, patients 
with a hypodensity of >50% of the middle cerebral artery are excluded for intervention, so the 
lesion size might be artificially smaller in those patients. (a territory >50% of the cerebellum 
is also an exclusion criterium, but that doesn't influence NIHSS as much) This finding at least 
confirms the benefit of thromblysis regardless of the stroke severity. In severe strokes, most 
patients have large occluding thrombi in intracranial arteries, which may need endovascular 
treatment for effective recanalisation; although only few of our patients underwent such 
treatments, an effective recanalisation strategy should be offered to severe stroke patient, 
particularly if the relationship between viable brain tissue and core is favourable. 
Obviously patients with a higher pre-stroke mRS will have a higher post-stroke mRS at 
3months, regardless of other factors, as the multivariate analysis showed. 
Studying the dynarnics of prognostic factors in severely presenting stroke, our study showed 
that the subacute phase seems very important when considering independence as outcome : 
acute temperature is still a value influencing patients' outcome regardless of when the 
assessement is done, and subacute glucose value is shown to be of main interest, since the 
results of our study seems to emphasize the management of hyperglycemia after 24h, once the 
patient is out of the emergency room. Hypergylcemic, not only diabetic patients, have a worse 
stroke outcome, since values >7.3 mmol/L are already associated with poor outcome50, we 
show here the same effect in the subacute phase. Thus, establishing guidelines in stroke units 
regarding aggressive i.v insulinotherapy already when glycemia exceeds this value and 
defining the transition from i.v. to subcutaneous insulin treatement, is recommended after 
what we have shown here. Age is retrieved in our subacute analysis of prediction factors, 
meaning that it is a deterrninant composant of good outcome in severely presenting stroke 
patients. 
Adding covariates from the subacute phase, we found previous clinical cerebrovascular events 
(stroke, TIA, retinal ischaemia) were independently associated with favourable outcome at 
three months. This was not explained by stroke mechanism but could indicate that patients 
who recovered from a previous stroke (rather than died) also have a better chance of recovery 
from a subsequent severe stroke; part of this may be due to genetics of neurovascular factors, 
anatomy of the cervico-cerebral vasculature including collaterals, or to ischaemic 
preconditioning 41 
Hypolipemic treatement: Even though this variable wasn't significant in the univariate 
analysis, in the mixed multivariate analysis for acute & subacute predictors, it was an 
independent predictor. This may be explained by pleiotropic effects of statins, especially on 
the cerebral vasculature. 
The overall recanalisation of occluded arteries is shown in the mixed multivariate analysis to 
be significant and this confirms the benefit maintaining permerability of cerebral vessels, 
regardless of the subacute characteristics of the patient51 , if the aim is to have a better 
independance of the patient at 3months. 
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5. Conclusion 
The analysis of the above mentioned factors has allowed to better understanding of risk 
factors, pathogenesis, and clinico-radiological patterns in patients with severely presenting 
stroke. It has therefore the potential to propose better preventive measures and appropriate 
treatment options. 
Our results show that pre-stroke caracteristics of the patient, stroke etiology, hematological 
values of the patient, and acute radiological findings, influence the risk to develop a severely 
presenting stroke. Although some of the results were expected, some are unconsistent with 
previous work on the topic, such as decrease of hemoglobin, absence of chronic brain lesions 
or old strokes, and the absence of influence of age and blood pressure. The clinical evolution 
of these patients was significantly worse, despite the increased frequency of interventions. 
When analysing severely presenting strokes outcome in the severely presenting stroke group, 
it helped us understand whether the patient's neurological evolution when having a severely 
presenting stroke was to be influenced by its management in the emergency room, in the 
radiology lab or at the ward regarding the subacute period. Our work confirms a recent study 
showing that acute patient management in the subacute phase influences tightly outcome after 
stroke52, which is shown by the fact that we find in the multivariate analysis characteristics 
that can be influenced by acute and subacute treatement, and secondary prevention, such as 
acute temperature, Glucose levels in the acute and subacute phases, hypolipemic medication, 
emergency treatement such like thrombolysis, and its success as vessel recanalisation. 
Despite the fact that the subgroup of severely presenting strokes were destined to have a bad 
outcome, nevertheless, some have a good outcome and it is our work as clinicians to target 
them quickly, to manage them with the most appropriate therapy and to follow them thightly 
at the ward, and this is the only manner to give them a chance of independence in the post-
stroke period. 
This confirms the fact that acute ischemic stroke patients have to be taken care of in a Stroke 
Unit, and that Stroke has to be considered as an emergency like myocardial infarction. 
Limitations of our work are the following: 
One limitation of our work is its observational, single centre design. Furthermore, we did not 
include detailed analysis of perfusion imaging studies nor of collaterals in our analysis even 
though such factors were shown to be linked to outcome prediction in stroke patients53. The 
fact that only a few patients had endovascular treatment limited the ability to explore its 
effects; recanalisation (spontaneous or thrombolysis related) was frequently measured, 
however, and showed significant associations 
with favourable outcome. We also accept that the NIHSS criterion of 20 and above causes 
slight under represention of right hemispheric strokes (67 = 33% in group S vs. 716 = 46% in 
0), due to the inherent definition of this scale. 
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Summary. Background: Severe stroke carries high rates of 
mortality and morbidity. The aims of this study were to 
detennine the characteristics of patients who initially presented 
with severe ischemic stroke, and to identify acute and subacute 
predictors of favorable clinical outcome in these 
patients. l\1ethods: An observational cohort study, Acute 
Stroke Registry and Analysis of Lausanne (ASTRAL), was 
analyzed, and ail patients presenting with severe stroke -
defined as a National Institute of Health Stroke Scale score of 
::0: 20 on admission - were compared with ail other patients. In a 
multivariate analysis, associations with demographic, clinical, 
pathophysiologic, metabolic and neuroimaging factors were 
determined. Furthe1111ore, we analyzed predictors of favorable 
outcome (modified Rankin scale score of:::; 3 at 3 months) in the 
subgroup of severe stroke patients. Results: Of 1915 consecu-
tive patients, 243 (12.7%) presented with severe stroke. This was 
significantly associated with cardio-embolic stroke mechanism 
(odds ratio [OR] 1.74, 95% confidence interval [CI] 1.19-2.54), 
unknown stroke onset (OR 2.35, 95% CI 1.14--4.83), more 
neuroimaging signs of early ischemia (mostly computed 
tomography; OR 2.65, 95% CI 1.79-3.92), arterial occlusions 
on acuteimaging (OR 27.01, 95% CI 11.5-62.9), fewerchronic 
radiologie infarcts (OR 0.43, 95% CI 0.26--0.72), lower hemo-
globin concentration (OR 0.97, 95% CI 0.96--0.99), and higher 
white cell count (OR 1.05, 95% CI 1.00-1.11). In the 68 (28%) 
patients with favorable outcomes despite presenting with severe 
stroke, this was predicted by lower age (OR 0.94, 95% CI 0.92-
0.97), preceding cerebrovascular events (OR 3.00, 95% CI 
1.01-8.97), hypolipemic pretreatment (OR 3.82, 95% CI 1.34-
10.90), lower acute temperature (OR 0.43, 95% CI 0.23-0.78), 
lower subacute glucose concentration (OR O. 74, 95% CI 0.56-
0.97), and spontaneous or treatment-induced recanalization 
(OR 4.51, 95% CI 1.96-10.41). Conclusions: Severe stroke 
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presentation is predicted by multiple clinical, radiologie and 
metabolic variables, several ofwhich are modifiable. Predictors 
in the 28% of patients with favorable outcome despite 
presenting with severe stroke include hypolipemic pretreatment, 
lower acute temperature, lower glucose levels at 24 h, and 
arterial recanalization. 
Keywords: cerebrovascular disease, computed tomography, 
outcome, severe, stroke, thrombolysis. 
Introduction 
Acute ischemic strokes with an initially severe neurologie deficit 
represent 2-10% [1] of ail ischemic strokes, and are associated 
with poor short-term and long-term prognoses. They are 
usually termed 'malignant' or 'massive' if the total territory of 
the middle cerebral artery is infarcted [2]. Such patients have a 
high 1isk of focal edema with herniation, systemic complica-
tions such as pneumonia [3], acute cardiac failure [4], and 
death. These strokes seem to be more frequently caused by 
cardiac ernboli and less frequently caused by large artery 
occlusive mechanisms than are less severe strokes [5]. In 
addition, increasing age, hyperglycemia and fever are often 
associated with worse outcomes. Although less evidence exists, 
several other factors may also predict a worse prognosis after 
stroke: premorbid disability, cognitive impairment, reduced 
consciousness at onset, certain acute clinical deficits, non-stroke 
unit care, and female gender [6]. The most consistently found 
predictors of long-term disability after ischemic stroke are 
increasing age and severity at onset [7]. Neuroimaging may 
represent a promising means to identify patients with poor 
outcome. The extent of early ischemic change on non-contrast 
computed tomography (CT) is associated with irreversible 
ischemia and prognosis [8-15]. In this study, we studied a 
population with clinically severe strokes. 
Few studies have systematically evaluated multimodal 
factors in unselected consecutive severe stroke patients. A 
better knowledge of the risk factors in the acute and the 
subacute phases and the relationship between patient charac-
te1istics and long-tern1 outcome would be useful for patient 
management. The objectives ofthis study were as follows: first, 
© 2012 International Society on Thrombosis and Haemostasis 
to study the sociodemographic, clinical, biological and radio-
logie factors that are associated with severe stroke in the acute 
phase; and second, to define predictors of good recovery in 
patients who presented with severe stroke. 
Methods 
Patients 
We used data from the Acute Stroke Registry and Analysis of 
Lausanne (ASTRAL). The ethics commission for research on 
humans of the Canton of Vaud, subcommission III, approved 
the scientific use of ASTRAL, which collected multiple datasets 
on ail acute ischemic stroke patients from the period 2004 to 
2010, defined arbitrarily as th ose presenting within 24 h after 
last-well time to the stroke unit and/or intensive care unit of 
Centre Hospitalier Universitaire Vaudois (CHUV) [16], which is 
a community hospital for a population of'"" 350 000, as well as 
the only stroke unit for 720 000 persons. In summary, we 
collected data on demographics, vascular risk factors, previous 
cerebrovascular events, prestroke disability, and medication at 
the time of stroke. Stroke pathophysiology was classified 
according to the TOAST classification [17]. The National 
Institute of Health Stroke Scale (NIHSS) score was prospec-
tively recorded for each patient on admission, and at 4-6 h, 
24 h, and 7 days, by NIHSS-certified medical personnel. Given 
the widespread use of the NIHSS to evaluate stroke severity, we 
used tllis scale with an arbitrary eut-off of2 20 on admission to 
define severe strokes. As is the case for mild stroke, there is no 
consensus on how to define severe strokes. In this study, we 
propose this term for clinically severe strokes, and we used a cut-
off of an NIHSS score of 2 20 points at presentation, while 
being aware of the limitations of the NIHSS grading of strokes 
associated with different cerebrovascular locations [16]. Meta-
bolic and hematologic parameters and vital signs were recorded 
in the registry on arrivai, and again at 24-48 h after stroke onset. 
Finally, we recorded silent lesions, leukoaraiosis and early 
ischemic lesions on acute imaging (mostly CT), as well as 
> 50% arterial stenosis or occlusion in cervical and cerebral 
arteries on acute imaging (mostly CT angiography). Most 
patients also underwent repeat parenchymal (magnetic reso-
nance imaging or CT) and arterial imaging (by magnetic 
resonance angiography [MRA], computerized tomography 
angiography [CT A], or Doppler) in the subacute or chronic 
phase after stroke. The modified Rankin score (mRs) was 
assessed by mRs-certified personnel at 3 months in the outpa-
tient clinic. At 12 rnonths, and for patients unable to attend the 
3-month outpatient clinic, mRs was assessed by a structured 
telephone interview by mRs-certified personnel. Acute stroke 
management and secondary prevention of these patient fol-
lowed current European Stroke Organization guidelines [18]. 
Statistica! analyses 
In the first part of this study, ail ASTRAL patients were 
separated into a group with a severe stroke (S) with an 
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admission NIHSS score of 2 20, or other comparison group 
(0). We analyzed ail demographic, clinical, biological and 
radiologie factors (total of 67 variables) that were readily 
available in the acute phase of stroke and were collected in 
ASTRAL. 
For the second part ofthis study, ail patients in the S group 
were separated into a group with a relatively favorable 
outcome and a group with an unfavorable outcome. Favorable 
outcorne was defined as an mRS score of :-::; 3, which is a 
common eut-off value in studies of severe stroke, such as 
hemorrhagic or posterior fossa stroke studies, and, given the 
initially severe clinical picture, made it a priori Jess probable 
that an mRS score of 0, 1 or 2 would be acllieved. We first 
studied the factors from the acute phase that may be associated 
in severe stroke with a favorable outcome, and then added 
variables collected in the subacute phase (24-48 h after stroke), 
including subacute NIHSS values, metabolic values, recanali-
zation on repeat arterial imaging, and parenchymal findings in 
subacute neuroimaging. 
For univariate comparison, we used Student's /-test for 
no1111ally distributed continuous data, and the Wilcoxon test 
for skewed distributions. For the categorical data, we used the 
chi-squared test. Ali variables with P-values of < 0.1 in the 
univariate analysis were entered into a multivariate logistic 
regression mode! to identify independent predictors. Using the 
significant variables in the multivariate analysis, we calculated 
the areas under the receiver operating characteristic curves 
(ROC-AUCs) for the two analyses. The level of significance 
was set at 95%. Ali data analyses were conducted by a 
statistician of the Institute of Social & Preventive Medicine at 
the CHUV, with STATA version 9.2, 2001 (Stata, College 
Station, TX, USA). 
Results 
Two hundred and forty-three of 1915 (12.7%) consecutive 
stroke patients had presented with severe stroke. Regarding the 
58 factors examined from the acute phase, there were 
important baseline differences between the S and 0 groups 
(selected variables are shown in Table 1). Patients in the S 
group were more likely to be female (53.50%), to have atrial 
fibrillation, and to have a low ejection fraction. Higher 
percentages of dissection and cardiac etiology were found in 
these patients, none of whom had lacunar stroke. Also, the 
proportion of patients with unlmown day of onset of syrnp-
toms was lligher in the the S group than in the 0 group, as was 
the proportion of patients with prestroke disability and pre-
existing neurologie deficit. Hypertension and chronic ischemic 
lesions were Jess frequent in the S group, but occlusion or 
stenosis of the cervical and/or cerebral vessels in the ischemic 
territory was more frequent in the S group. Patients in the S 
group had lligher heart rates and leukocytosis at adnlission, but 
lower body temperature, hemoglobin levels, and hematocrit. 
Multivariate analysis yielded seven stroke-related, metabolic 
and radiologie variables that were independently associated 
with severe stroke (Table 2). The ROC-AUC for predicting 
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Table 1 Selected patient characteristics in the acute phase in the 'severe' and 'others' groups with univariate comparisons 
Patient characteristics Ali (11 = 1915) Severe (11 = 243) Others (11 = 1672) OR P-value 
Demographics 
Age (years), mean ( ± SD) 68.8 (15.4) 69.6 (16.8) 68.7 (15.2) 1.00 0.37 
Female sex 840 (43.9) 130 (53.5) 710 (42.5) 0.64 < 0.01 
Prestroke disability (measured with mRS) 0 (!) 0 (1) 0 (!) 1.17 0.01 
NIHSS and its course 
Prestroke neurologie deficit (measured with NIHSS) 0 (0) 0 (0) 0 (0) 1.13 0.03 
Admission NIHSS score 6 (11) 23 (5) 5 (7) 
NIHSS score at 4-6 h after arriva! 5 (9) 23 (6) 4 (7) 1.55 < 0.01 
NIHSS score at 24 h 4 (9) 22 (8) 3 (6) 1.31 < 0.01 
NIHSS score at 7 days 3 (8) 22 (21) 2 (4) 1.15 < 0.01 
Risk factors (pre-existing or newly discovered) 
Hypertension 1280 (66.9) 140 (57.8) 1140 (68.2) 0.63 < 0.01 
Dia be tes mellitus 303 (15.9) 33 (13.7) 270 (16.2) 0.82 0.33 
Active smoking 444 (23.5) 46 (19.8) 398 (24.0) 0.78 0.16 
Atrial fibrillation 482 (25.2) 94 (38.8) 388 (23.2) 2.09 < 0.01 
Coronaiy heart disease 284 (14.8) 37 (15.2) 247 (14.7) 1.03 0.86 
Low ejection fraction ( < 35%) 85 (4.5) 20 (8.6) 65 (3.9) 2.27 0.02 
Previous cerebrovascular event (stroke, TIA, or retinal) 28 (1.4) 3 (1.2) 25 (1.5) 0.77 0.11 
Medication at admission 
Antiplatelet 681 (35.9) 81 (33.8) 600 (36.2) 0.90 0.48 
Anticoagulant 192 (10.1) 29(12.1) 163 (9.8) 1.26 0.28 
Antihypertensive 1045 (55.2) 123 (51.9) 922 (55.7) 0.85 0.27 
Hypolipemic 438 (23.1) 41 (17.2) 397 (24.0) 0.65 0.02 
Antidiabetic 155(8.l) 14 (5.8) 141 (8.5) 0.66 0.16 
Stroke onset during night sleep 445 (23.2) 49 (20.1) 396 (23.7) 0.81 0.22 
Unknown stroke onset, not sleep 97 (5.0) 32 (13.1) 65 (3.8) 3.74 < 0.01 
Stroke mechanism 
A therosclerosis 254 (13.6) 30 (12.5) 224 (13.7) 0.90 0.61 
Unknown 458 (24.5) 50 (20.9) 408 (25.0) 0.91 0.72 
Cardiac (including patent foramen ovale as the likely cause) 617 (33.0) 118 (49.3) 499 (30.6) 1.76 0.01 
Lacunar 277 (14.8) 0 (0) 277 (17.0) 
Dissection 92 (4.9) 18 (7.5) 74 (4.7) 1.81 0.07 
Other and rare causes 77 (4.1) 11 (4.6) 66 (4.0) 1.24 0.56 
Multiple and coexisting causes 92 ( 4.9) 12 (5.0) 80 ( 4.9) 1.02 0.76 
Radiologie findings 
Acute parenchymal findings 632 (35.5) 149 (63.4) 483 (31.2) 3.80 < 0.01 
Chronic radiologie strokes 514 (30.8) 55 (24.5) 459 (31.7) 0.69 0.03 
Significant arterial findings in ischemic territory 796 (49.9) 616 (88.2) 180 (44.2) 9.43 < 0.01 
Metabolic values at admission 
Admission systolic blood pressure (mmHg), mean ( ± SD) 158.87 (28.5) 156.44 (31.4) 159.22 (28.0) 0.99 0.16 
Admission heart rate (min-1), mean ( ± SD) 79.97 (18.0) 83.78 (22.3) 79.41 (17.2) 1.01 < 0.01 
Admission temperature (0 C), mean ( ± SD) 36.39 (0.6) 36.26 (0.8) 36.41 (0.6) 0.70 < 0.01 
Admission glucose (mM), mean ( ± SD) 7.17 (2.9) 7.55 (2.3) 7.11 (3.0) 1.03 0.05 
Admission hemoglobin (g L-1), mean ( ± SD) 138. 77 (32.8) 132.86 (19.6) 139 .65 (34.3) 0.98 < 0.01 
Admission white cell count (103 L-1), mean ( ± SD) 8.65 (4.4) 9.83 (4.7) 8.48 ( 4.3) 1.06 < 0.01 
Interventions and outcome 
Intravenous thrombolysis 302 (15.7) 72 (29.6) 230 (13.7) 2.72 < 0.01 
Endovascular treatment 16 (0.8) 7 (2.8) 9 (0.5) 6.77 < 0.01 
Craniectomy 15 (0.7) 9 (3. 7) 6 (0.3) 10.66 < 0.01 
mRS score at 3 months 2 (3) 5 (3) 1 (2) 1.93 < 0.01 
Favorable outcome (mRS score at 3 months of 0-3) 1405 (73) 68 (2) 1337 (7) 0.10 < 0.01 
mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Scale; OR, odds ratio; SD, standard deviation; TIA, transient ischemic 
attack. Values are expressed as median and interquartile range for continuons variables, or absolute count and percentage for categorical variables, 
unless stated otherwise. 
severe strokes was 86% with the significant variables from the 
acute phase. 
Sixty-eight of 243 (28.0%) of consecutive severe stroke 
patients had a favorable outcome at 3 months. Selections of the 
63 acute and 31 subacute variables examined are shown in 
Tables 3 and 4, respectively. In a multivariate analysis of the 
acute phase (Table 5), favorable outcome was predicted by 
lower age and lower initial temperature. Private insurance 
status, lower pre-existing functional handicap, lower glycemia 
and recanalization treatment also increased the probability of 
favorable outcome. When subacute variables were added into 
the multivariate analysis (Table 6), treatment with hypolipemic 
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Table 2 Multivariate analysis of factors significantly associated with S 
Factors OR (95% CI) P-value 
Cardioembolic stroke 1.74 (1.19-2.54) < 0.01 
Unknown onset of stroke 2.35 (1.14-4.83) 0.02 
(but not wake-up strokes) 
Early ischernic changes on 2.65 (1.79-3.92) < 0.01 
initial imaging 
Chronic strokes on imaging 0.43 (0.25--0.71) < 0.01 
Significant arterial findings 27.01 (11.59-62.92) < 0.01 
in ischemic territory 
Hemoglobin (g L-1) 0.97 (0.96--0.98) < 0.01 
White cell count (x 103 L-1) 1.05 (1.00-1.10) 0.04 
CI, confidence interval; OR, odds ratio. 
agents (mostly statins) increased the probability of favorable 
outcome. The pre-existing functional handicap was replaced by 
past cerebrovascular events, acute by subacute (24-48 h) 
glycemia, and recanalization treatment by (therapeutic or 
spontaneous) recanalization. The ROC-AUCs for predicting 
favorable outcome after severe stroke with the acute vaiiables 
were 82% and 81 % when the subacute variables were added. 
Discussion 
Using a large number of sociodemographic, clinical, radio-
logie and metabolic variables, we have identified seven 
factors that are associated with severe stroke at the time of 
emergency room admission. Furthermore, we found that 
favorable outcome despite the patient initially presenting with 
severe stroke was associated, with a high degree of 
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confidence, with demographic and metabolic factors and 
early recanalization. 
When examining the profile of patients who suffer severe 
stroke, we found cardio-embolic origin of stroke to be 
significantly associated with these patients, similarly to previous 
studies [19-21]. This may be explained by the usual size of 
cardiac emboli as well as by the lack of collateral vasculariza-
tion, which may develop and compensate for acute arterial 
occlusion in patients with graduai occlusion of arteries, such as 
in atherosclerosis of cervical or cerebral arteries. In the 
univariate, but not the multivariate, analysis, we also found 
dissection to be associated with severe stroke. It is of note that 
there were no patients with lacunar stroke among those 
presenting with severe stroke. 
We found that severe strokes were more frequently of 
unknown time of onset, but only if they were not associated 
with sleep onset. This is possibly related to the fact that such 
patients were not alert and were unable to express details of 
their stroke onset. The reason why this is not the case for sleep-
onset stroke may be that such strokes are more frequently 
lacunar [22]. Severe strokes were more frequent in patients with 
lower hemoglobin levels, suggesting that decreased oxygen 
transport capacity may increase infarct size, consistent with a 
previous report [23]. White cell count has previously been 
associated with a more severe clinical presentation and with a 
worse early stroke outcome [24]. lt is not clear whether this is a 
direct effect of white cell activity and inflammation in the 
lesioned brain, or whether it is rather a marker of associated 
conditions (e.g. fever, early infection, or stress response) that 
may increase stroke severity and worsen outcome. 
Table 3 Selected patient characteristics in the acute phase in the favorable outcome and unfavorable outcome groups, with univariate comparisons 
Unfavorable 
Favorable outcome outcome (mRS score 
Ail patients (mRS score of 0--3 at of 4-6 at 3 months: 
Patient characteristics (n = 243) 3 months: 11 = 68) Il = 175) OR P-value 
Age (years), median ( ± IQR) 69.6 (16.88) 72.8 (16.1) 61.4 (16.2) 0.96 < 0.01 
Private insurance 42 (17.4) 17 (25.0) 25 (14.4) 1.97 0.06 
mRS score prestroke, median ( ± IQR) 0 (!) 0 (0.5) 1 (2) 1.17 0.01 
Hypolipemic treatment on admission 41 (17.2) 15 (22.7) 26 (15.1) 1.65 0.17 
Unknown stroke onset (not sleep) 32 (13.1) 7 (10.2) 25 (14.2) 0.68 0.41 
Acute parenchymal findings 149 (63.4) 37 (56.9) 112 (65.8) 0.68 0.20 
Chronic radiologie strokes 55 (24.5) 13 (21.6) 42 (825.6) 0.80 0.54 
Significant arterial findings in ischemic 180 (88.2) 56 (90.3) 124 (87.3) 1.35 0.54 
terri tory 
Systolic blood pressure (mmHg) 156.44 (31.4) 149.41 (28. 7) 159 .19 (32.0) 0.98 0.03 
Temperature (°C) 36.26 (0.8) 36.07 (0.6) 36.33 (0.8) 0.63 0.02 
Glucose (mM) 7.55 (2.3) 6.85 (1.8) 7.82 (2.5) 0.81 0.01 
White blood cell count (x 103 L-1) 9.83 (4.7) 9.93 (4.7) 9.79 (4.7) 1.00 0.84 
Total cholesterol (mM) 5.59 (4.4) 5.08 (1.5) 5.77 (5.0) 0.94 0.37 
IVT 72 (29.6) 32 (47.0) 40 (22.8) 3.30 < 0.01 
EVT 7 (2.8) 3 (5.8) 3 (1.7) 5.50 0.03 
IVT or EVT 79 (32.5) 36 (52.9) 43 (24.5) 3.45 < 0.01 
Timing of intervention (min) 152.1 (91.6) 13.41 (4.9) 13.00 (5.4) 1.00 0.39 
Craniectomy 9 (3.7) 3 ( 4.4) 6 (3.4) 1.30 0.72 
EVT, endovascular treatment; IQR, interquartile range; IVT, intravenous thrombolysis; mRS, modified Rankin scale; OR, odds ratio. Values are 
expressed as mean and standard deviation for continuous variables, or absolute count and percentage for categorical variables, unless stated 
otherwise. 
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Table 4 Selected factors of the acute phase in the favorable outcome and unfavorable outcome groups, with univariate comparisons 
Favorable outcome Unfavorable outcome 
(mRS score of 0-3 (mRS score of 4-6 
Patient characteristics Ali patients at 3 months) at 3 months) OR P-value 
N(%) 243 (100) 69 (28) 174 (72) 
Subacute imaging findings at 24-48 h 
Any stroke-related findings 150 (96.1) 51 (92.7) 99 (98.0) 0.25 0.13 
(ischemia and/or hemorrhage)* 
Any hemorrhagic 29 (18.9) 10 (18.5) 19 (19.1) 0.95 0.919 
transformation (symptomatic 
or not) 
Symptomatic hemorrhagic 6 (3.9) 0 (0.0) 6 (6.0) 
transformation according ta 
ECASS-2 definition 
Subacute vascular imaging at 24-48 h 
Significant arterial findings in 78 (67.2) 27 (60.0) 51 (71.8) 0.58 0.19 
ischemic territory 
Partial or complete 66 (28.3) 35 (51.4) 31 (18.7) 4.58 < 0.01 
recanalization of cervical 
and/or cerebral arteries 
(where assessed) 
Excracranial recanalization 20 (8.5) 6 (8.8) 14 (8.4) 1.05 0.92 
(complete, partial) 
Intracranial recanalization 63(27.1) 37 (54.4) 26 (15.8) 6.33 < 0.01 
( complete, partial) 
Subacute metabolic values at 24-48 h 
Systolic blood pressure (mmHg) 143 .4 7 (21.9) 139.78 (21.9) 145.07 (21.8) 0.98 0.1 
Diastolic blood pressure 68. 70 (15.6) 67.55 (15.7) 69.19 (15.5) 0.99 0.472 
(mmHg) 
Heart rate (min-1) 82.55 (18.3) 76.25 (16.6) 85.26 (18.3) 0.97 < 0.01 
Temperature (0 C) 37.01 (0.7) 36.89 (0.7) 37.06 (0.6) 0.69 < 0.01 
Glucose (mM) 6.41 ( 1.9) 5.93 (1.2) 6.65 (2.1) 0.77 0.02 
Senan creatinine (mM) 89.53 (71.7) 79.19 (25.4) 93.48 (82.6) 0.99 0.16 
Hemoglobin (g L- 1) 126.59 (19.5) 124.48 (20.7) 127.53 (19.0) 0.99 0.4 
Hematocrit mean ( ± SD) 38.04 (5.3) 37.19(5.3) 38.41 (5.3) 0.95 0.22 
Total cholesterol (mM) 8.12 (9.3) 4.84 (1.0) 9.76 (11.2) 0.90 0.35 
White blood cell 11.21 (3.9) 10.69 (3.3) 11.45(4.1) 0.94 0.29 
count (x 103 L-1) 
Platelet count (x 103 L-1) (mean) 215.95 (74.3) 218.71 (67.4) 214.71 (77.5) 1.00 0.77 
NIHSS score at 7 days, median 22 (21) 12 (15) 24 (24) 0.85 < 0.01 
(± IQR) 
Discharge* 
De a th 84 (36.5) 0 (0) 84 (50.9) 
Home 11 (4.7) 9 (13.8) 2 (1.2) 13 < 0.01 
Long-term institution 14 (6.0) 0 (0) 14 (8.4) 
Transfer ta other acute-care 41 (17.8) 19 (29.2) 22 (13.3) 2.68 < 0.01 
service or hospital 
Rehabilitation hospital 80 (34.7) 37 (56.9) 43 (26.0) 3.74 < 0.01 
IQR, interquartile range; mRS, modified Rankin scale; OR, odds ratio; SD, standard deviation. Values are expressed as mean and SD for 
continuous variables, or absolute count and percentage for categorical variables, unless stated otherwise. *Not included in the multivariate analysis. 
Radiologie data revealed that early signs of parenchymal 
ischemia and notable clinical findings within arteries of the 
ischemic region (e.g. occlusion or > 50% stenosis) are 
observed significantly more frequently in patients with severe 
stroke, again confirming the findings of previous studies 
[25,26]. 
We also found that chronic strokes on neuroimaging are less 
frequent among severe stroke patients. This seems counterin-
tuitive, given that functional compensation for cerebral damage 
depends partially on the remaining 'healthy' brain. However, 
patients who have less severe strokes might have a higher 
likelihood of having survived other minor strokes in the past. 
In addition, such survivors of previous strokes may receive 
better secondary prevention treatments, which have been 
shown to decrease not only recurrence, but also the severity 
of recurrent strokes [27-30]. 
Although female gender and increased heart rate were more 
frequent in those patients presenting with severe stroke by 
univariate analysis, these factors were not independent. Sim-
ilarly, pre-existing hypertension and pretreatment with hypol-
ipemic agents were negatively associated with severe stroke in 
the univariate, but not in the multivariate, analysis. Interest-
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Table 5 Multivariate analysis of acute-phase factors significantly associ-
ated with favorable ourtcome 
Factors 
Age 
Prestroke handicap (mRS) 
Private insurance status 
Acute temperature 
Acute glucose value 
Acute EVT within 
recommended time limits 
(IVT or EVT) 
OR (95% CI) 
0.95 (0.92--0.97) 
0.62 (0.40--0.95) 
2.51 (1.05-5.98) 
0.42 (0.23--0.74) 
0.74 (0.61--0.90) 
2.47 (1.20-5.08) 
P-value 
< 0.01 
0.03 
0.037 
< 0.01 
< 0.01 
0.01 
CI, confidence interval; EVT, endovascular treatment; IVT, intrave-
nous thrombolysis; mRS, modified Rankin scale; OR, odds ratio. 
Table 6 Multivariate analysis of factors of the acute and subacute phases 
combined that are significantly associated with favorable outcomeF 
Factor OR (95% CI) P-value 
Age 0.94 (0.91-0.97) < 0.01 
Previous cerebrovascular event 3.00 (1.00-8.96) 0.04 
(stroke, TIA, retinal ischemia) 
Hypolipemic treatement at 3.82 (1.34-10.89) 0.01 
stroke onset 
Acute temperature 0.42 (0.23--0.78) < 0.01 
Subacnte glucose values 0.73 (0.56--0.96) 0.02 
at 24-48 h 
Recanalization of cervical 4.51 (1.95-10.40) < 0.01 
and/or intracranial arteries 
(partial or complete) 
CI, confidence interval; OR, odds ratio; TIA, transient ischemic attack. 
ingly, age, pre-existing risk factors, such as hypertension, 
diabetes, or smoking, and insurance status were not associated 
with severe stroke. 
As an additional observation, the in-hospital course of 
NIHSS score differed between the two groups: in the Jess severe 
strokes, NIHSS score measured at 4 h, 24 h and 7 days showed 
a decreasing pattern from the beginning, which was not the 
case for severe strokes, where the NIHSS score remained 
elevated for the first 7 days. This result is probably attributable 
to an increased rate of complications in severe stroke patients, 
such as brain edema, hemorrhagic transformation (HT), and 
medical complications [1,2,31,32]. Regarding HT according to 
the ECASS-2 definition, unfavorable outcome was associated 
with greater HT. 
Given that stroke severity is one of the most significant 
independent predictors of poor short-term and long-term 
outcome [33-35], we were interested in analyzing predictors of 
favorable outcome after 3 months in patients with severe 
stroke. 
As expected, higher age and prestroke handicap (as 
measured by previous mRS score) were associated with a 
reduced likelihood of achieving a favorable outcome at 
3 months in severe stroke patients. A reduction in the number 
of synapses in old age [36] and a dimüùshed volume of cortical 
gray matter [37] may hinder recovery, because of limited 
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neuronal plasticity. Also, acute initial temperature and elevated 
glucose levels had a negative influence on outcome, as 
previously shown [38,39]. The relationship between tempera-
ture, inflammation, stroke seveiity and stroke outcome is 
currently being elucidated [40]. However, stroke severity may 
be more frequently associated with dysphagia during the acute 
phase, which may lead to aspiration pneumonia and further 
worsening of stroke outcome [41 ]. 
Private insurance status - probably indicating a higher 
socioeconomic status - has previously been show to predict 
favorable outcome in stroke patients [42,43]. The reasons for 
tlùs observation are not certain, although one of our previous 
studies showed lower initial stroke severity in privately insured 
patients [42]; this was not confirmed in the current dichoto-
mized study. 
It is encouraging that recanalization also favorably infiu-
enced the fate of severe stroke patients. It has been hypoth-
esized that the decreased effect of intravenous thrombolysis in 
severe stroke may be related to insufficient recanalization 
[44,45]. Most patients with severe stroke have large occluding 
thrombi in intracranial arteries, wlùch may need endovascular 
treatment for effective recanalization [46]; although only few of 
our patients underwent such treatments, an effective recana-
lization strategy should be offered to severe stroke patients, 
particularly if the relationslùp between viable brain tissue and 
core is favorable [47]. 
When we added covariates from the subacute phase, we 
found that previous clinical cerebrovascular events (stroke, 
transient ischemic attack, and retinal ischemia) were indepen-
dently associated with favorable outcome at 3 months. This 
was not explained by the stroke mechanism, but could indicate 
that patients who recovered from a previous stroke (rather than 
died) also had a better chance of recovery from a subsequent 
severe stroke; this could be partly explained by the genetics of 
neurovascular factors, the anatomy of the cervico-cerebral 
vasculature, including collaterals, or ischemic preconditioning 
[48]. 
As recently shown for ischemic stroke of any severity, 
pretreatment with hypolipemic agents (mostly statins in our 
population) was also associated with favorable outcome [49]. 
This may be explained by the pleiotropic effects of statins, 
especially on the cerebral vasculature. Finally, hyperglycemia 
in the subacute phase seemed to be associated with 
unfavorable outcome at least as strongly as in the acute 
phase. This confirms previous observations of our group 
[50]. 
Interestingly, pre-existing risk factors and stroke etiology 
were not associated with 3-month outcome. 
One limitation of our work is its observational, single-center 
design. Furthe1111ore, we did not include a detailed analysis of 
perfusion imaging studies or of collaterals in our analysis, even 
though such factors have been shown to be linked to outcome 
prediction in stroke patients [51,52]. The fact that only a few 
patients had endovascular treatment limited the ability to 
explore its effects; recanalization (spontaneous or thromboly-
sis-related) was frequently measured, however, and showed 
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significant associations with favorable outcome. We also accept 
that the criterion of an NIHSS score of :2: 20 leads to a slight 
underrepresention of right hemispheric strokes (67 = 33% in 
the S group vs. 716 = 46% in the 0 group), owing to the 
inherent definition of this scale. 
In summary, our results show that prestroke characteristics 
of the patient, stroke etiology, hematologic values and acute 
radiologie and arterial findings are associated with severe 
stroke. Although some of the results were expected, others are 
new, and most can be influenced before or after onset of the 
severe stroke. As expected, severe stroke patients had a rather 
poor prognosis. Nevertheless, several factors associated with 
favorable outcome, such as lower acute temperature, lower 
glucose levels at 24 h, previous cerebrovascular events, and 
arterial recanalization, should encourage clinicians to treat such 
patients aggressively and to search for new treatrnent modal-
ities. 
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